India warns of risks as cheap generic weight-loss drugs flood market after Semaglutide patent expiry

India's health ministry has issued a warning over the unregulated use of generic GLP-1 weight-loss drugs like semaglutide, as patent expiry opens the floodgates to low-cost versions priced as little as $15 a month

from mint - science https://ift.tt/HFIcXsw